RÉSUMÉ
PURPOSE: To compare fluid replacement therapy with Hydroxyethyl starch 6% (HES) versus Ringer's lactate (RL) in a rodent model of non-septic renal ischemia. METHODS: Forty male Wistar rats were randomized to receive HES 2 ml.kg-1.hr-1or RL 5 ml. kg-1.hr-1 that underwent 30 minutes of renal ischemia followed by reperfusion. Twelve hours after kidney ischemia, the kidneys were evaluated for histological changes. Serum NGAL levels were obtained at different times of the experimental protocol. RESULTS: Rodents in the HES group had a median (IQR) grade of renal injury 3 (3 to 5) compared to 2 (2 to 4) in the RL group (p=0.03). NGAL levels were not associated with the severity of kidney injury. CONCLUSION: Hydroxyethyl starch administration caused more kidney injury than Ringer's lactate in a non-infectious model of renal hypoperfusion.
Sujet(s)
Animaux , Mâle , Rats , Atteinte rénale aigüe/thérapie , Hydroxyéthylamidons/usage thérapeutique , Ischémie/thérapie , Solution isotonique/usage thérapeutique , Rein/vascularisation , Substituts du plasma/usage thérapeutique , Protéine de la phase aigüe , Atteinte rénale aigüe/anatomopathologie , Traitement par apport liquidien/méthodes , Hémodynamique , Ischémie/anatomopathologie , Rein/anatomopathologie , Lipocalines/sang , Protéines oncogènes/sang , Répartition aléatoire , Rat Wistar , Reproductibilité des résultats , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
In this work, BCL-2 oncoprotein and sphingolipids levels were determined in blood of 60 children including 27 children with non- Hodgkin's lymphoma[NHL], 20 children with acute lymphoblastic leukemia [ALL] and 13 children with acute monoblastic leukemia [AML]. The study also included 11 healthy controls with comparable ages to patients. The study revealed significant increase in BCL-2 oncoprotein levels in patients compared with the controls; where levels in cases with AML were lower than cases with ALL or NHL. All patients had BCL-2 levels higher than cut-off levels i.e. 100% sensitivity. Children with enlarged liver and/or spleen showed higher BCL-2 oncoprotein levels compared with those without this enlargement. There was significant positive correlation between BCL-2 oncoprotein levels and splenic size. The levels of sphingolipids were significantly increased in patients compared with controls. Patients with ALL and NHL had significantly higher levels than cases with AML. Among cases with lymphoma and leukemia, 53.3% had levels above the cut-off levels. Children with liver and/or splenic enlargement had higher sphingolipid levels than children without enlargement. Sphingolipid levels correlated significantly in a positive manner with the size of the liver and spleen
Sujet(s)
Humains , Mâle , Femelle , Lymphome malin non hodgkinien/physiopathologie , /physiopathologie , Leucémie aigüe monoblastique/physiopathologie , Enfant , Protéines oncogènes/sang , Sphingolipides/sangRÉSUMÉ
This study tried to speculate the role of Apo-I antigen and BCL-2 oncoprotein in newly diagnosed children with acute lymphoblastic leukemia [ALL] and to find out if they have any possible role as predictors of the outcome and response to therapy. Before induction therapy Fas antigen expression had a significantly low mean value in the patients with failed induction compared with patients with complete remission. Patients with failed induction showed a significantly higher pre-induction value of patients who showed complete remission. No significant correlation was found between the percentage of Fas expression among patients with ALL was variable. In spite of having high values of Bcl-2, yet, neither Fas antigen expression nor the level of BCL-2 oncoprotein could be considered as a sensitive predictor of the outcome and response to therapy